Market Research Logo

Hepatitis C Treatment

Hepatitis C Treatment

Hepatitis C Treatment market worldwide is projected to grow by US$44.5 Billion, driven by a compounded growth of 12.9%. HCV Protease Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.2%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$8.9 Billion by the year 2025, HCV Protease Inhibitors will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 11.5% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$1.8 Billion to the region's size and clout in the next 5 to 6 years. Over US$1.5 Billion worth of projected demand in the region will come from Rest of Europe markets. In Japan, HCV Protease Inhibitors will reach a market size of US$176.5 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.2% over the next couple of years and add approximately US$10.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include among others, AbbVie, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; GlaxoSmithKline PLC; Johnson & Johnson; Kadmon Holdings, Inc.; Merck & Co., Inc.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Global Competitor Market Shares
Hepatitis C Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: Hepatitis C Treatment Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 2: Hepatitis C Treatment Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
TABLE 3: Hepatitis C Treatment Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
TABLE 4: HCV Protease Inhibitors (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 5: HCV Protease Inhibitors (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 6: HCV Protease Inhibitors (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
TABLE 7: HCV Polymerase Inhibitors (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
TABLE 8: HCV Polymerase Inhibitors (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
TABLE 9: HCV Polymerase Inhibitors (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
TABLE 10: HCV NS5A Inhibitors (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
TABLE 11: HCV NS5A Inhibitors (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
TABLE 12: HCV NS5A Inhibitors (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 13: Combination Therapy (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
TABLE 14: Combination Therapy (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
TABLE 15: Combination Therapy (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
TABLE 16: Interferon & Antiviral (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 17: Interferon & Antiviral (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 18: Interferon & Antiviral (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Hepatitis C Treatment Market Share (in %) by Company: 2019 & 2025
TABLE 19: United States Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 20: Hepatitis C Treatment Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 21: United States Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
CANADA
TABLE 22: Canadian Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 23: Canadian Hepatitis C Treatment Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 24: Hepatitis C Treatment Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
JAPAN
TABLE 25: Japanese Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 26: Hepatitis C Treatment Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 27: Japanese Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
CHINA
TABLE 28: Chinese Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 29: Hepatitis C Treatment Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017
TABLE 30: Chinese Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
Market Facts & Figures
European Hepatitis C Treatment Market: Competitor Market Share Scenario (in %) for 2019 & 2025
TABLE 31: European Hepatitis C Treatment Market Demand Scenario in US$ Million by Region/Country: 2018-2025
TABLE 32: Hepatitis C Treatment Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
TABLE 33: European Hepatitis C Treatment Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
TABLE 34: European Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 35: Hepatitis C Treatment Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 36: European Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
FRANCE
TABLE 37: Hepatitis C Treatment Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 38: French Hepatitis C Treatment Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 39: French Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
GERMANY
TABLE 40: Hepatitis C Treatment Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 41: German Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 42: German Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
ITALY
TABLE 43: Italian Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 44: Hepatitis C Treatment Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017
TABLE 45: Italian Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
TABLE 46: United Kingdom Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 47: Hepatitis C Treatment Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 48: United Kingdom Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
SPAIN
TABLE 49: Spanish Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 50: Spanish Hepatitis C Treatment Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 51: Hepatitis C Treatment Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
RUSSIA
TABLE 52: Russian Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 53: Hepatitis C Treatment Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 54: Russian Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
REST OF EUROPE
TABLE 55: Rest of Europe Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 56: Hepatitis C Treatment Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 57: Rest of Europe Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
ASIA-PACIFIC
TABLE 58: Asia-Pacific Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 59: Hepatitis C Treatment Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017
TABLE 60: Asia-Pacific Hepatitis C Treatment Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025
TABLE 61: Hepatitis C Treatment Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 62: Asia-Pacific Hepatitis C Treatment Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 63: Asia-Pacific Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
AUSTRALIA
TABLE 64: Hepatitis C Treatment Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 65: Australian Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 66: Australian Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
INDIA
TABLE 67: Indian Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 68: Indian Hepatitis C Treatment Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 69: Hepatitis C Treatment Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
SOUTH KOREA
TABLE 70: Hepatitis C Treatment Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 71: South Korean Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 72: Hepatitis C Treatment Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
TABLE 73: Rest of Asia-Pacific Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 74: Hepatitis C Treatment Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 75: Rest of Asia-Pacific Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
LATIN AMERICA
TABLE 76: Latin American Hepatitis C Treatment Market Trends by Region/Country in US$ Million: 2018-2025
TABLE 77: Hepatitis C Treatment Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017
TABLE 78: Latin American Hepatitis C Treatment Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025
TABLE 79: Latin American Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 80: Hepatitis C Treatment Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017
TABLE 81: Latin American Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
ARGENTINA
TABLE 82: Argentinean Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 83: Hepatitis C Treatment Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 84: Argentinean Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
BRAZIL
TABLE 85: Hepatitis C Treatment Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 86: Brazilian Hepatitis C Treatment Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 87: Brazilian Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
MEXICO
TABLE 88: Hepatitis C Treatment Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 89: Mexican Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 90: Mexican Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
TABLE 91: Rest of Latin America Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 92: Hepatitis C Treatment Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 93: Rest of Latin America Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
MIDDLE EAST
TABLE 94: The Middle East Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 95: Hepatitis C Treatment Market in the Middle East by Region/Country in US$ Million: 2009-2017
TABLE 96: The Middle East Hepatitis C Treatment Market Share Breakdown by Region/Country: 2009, 2019, and 2025
TABLE 97: The Middle East Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 98: The Middle East Hepatitis C Treatment Historic Market by Drug Class in US$ Million: 2009-2017
TABLE 99: Hepatitis C Treatment Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
IRAN
TABLE 100: Iranian Market for Hepatitis C Treatment: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 101: Hepatitis C Treatment Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 102: Iranian Hepatitis C Treatment Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
ISRAEL
TABLE 103: Israeli Hepatitis C Treatment Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 104: Hepatitis C Treatment Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 105: Israeli Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
SAUDI ARABIA
TABLE 106: Saudi Arabian Hepatitis C Treatment Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 107: Hepatitis C Treatment Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017
TABLE 108: Saudi Arabian Hepatitis C Treatment Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED ARAB EMIRATES
TABLE 109: Hepatitis C Treatment Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 110: United Arab Emirates Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 111: Hepatitis C Treatment Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025
REST OF MIDDLE EAST
TABLE 112: Hepatitis C Treatment Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 113: Rest of Middle East Hepatitis C Treatment Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 114: Rest of Middle East Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
AFRICA
TABLE 115: African Hepatitis C Treatment Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 116: Hepatitis C Treatment Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 117: African Hepatitis C Treatment Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
IV. COMPETITION
ABBVIE
BRISTOL-MYERS SQUIBB COMPANY
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
KADMON HOLDINGS, INC.
MERCK & CO., INC.
V. CURATED RESEARCH

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook